Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

J. Gligorov, B. Ataseven, M. Verrill, M. De Laurentiis, K. H. Jung, H. A. Azim, N. Al-Sakaff, S. Lauer, M. Shing, X. Pivot, SafeHer Study Group, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. Together they form a unique fingerprint.

Medicine & Life Sciences